MX342322B - Compuestos organicos. - Google Patents
Compuestos organicos.Info
- Publication number
- MX342322B MX342322B MX2014000255A MX2014000255A MX342322B MX 342322 B MX342322 B MX 342322B MX 2014000255 A MX2014000255 A MX 2014000255A MX 2014000255 A MX2014000255 A MX 2014000255A MX 342322 B MX342322 B MX 342322B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- organic compounds
- nicotinic receptor
- treatment
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 229940123859 Nicotinic receptor antagonist Drugs 0.000 abstract 1
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/041866 WO2012177263A1 (en) | 2011-06-24 | 2011-06-24 | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| US201161501207P | 2011-06-25 | 2011-06-25 | |
| PCT/US2012/043880 WO2012178112A1 (en) | 2011-06-24 | 2012-06-22 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000255A MX2014000255A (es) | 2014-08-21 |
| MX342322B true MX342322B (es) | 2016-09-23 |
Family
ID=47422974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000255A MX342322B (es) | 2011-06-24 | 2012-06-22 | Compuestos organicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9108949B2 (https=) |
| EP (1) | EP2723173B1 (https=) |
| JP (1) | JP6087911B2 (https=) |
| KR (1) | KR20140036305A (https=) |
| CN (1) | CN103717069B (https=) |
| AU (2) | AU2012272646B2 (https=) |
| BR (1) | BR112013033306A2 (https=) |
| CA (2) | CA2840373A1 (https=) |
| ES (1) | ES2627338T3 (https=) |
| IL (1) | IL230036A (https=) |
| MX (1) | MX342322B (https=) |
| RU (1) | RU2610094C2 (https=) |
| WO (3) | WO2012177263A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012177263A1 (en) * | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| US11491150B2 (en) | 2017-05-22 | 2022-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019152680A1 (en) * | 2018-01-31 | 2019-08-08 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using chrna6 inhibitors |
| US12396992B2 (en) | 2019-01-07 | 2025-08-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2021008565A1 (zh) * | 2019-07-16 | 2021-01-21 | 清华大学 | 乙酰胆碱通路调节剂在治疗癌症中的用途 |
| AU2020343329C1 (en) | 2019-09-03 | 2026-02-12 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| EP4238970A1 (en) * | 2022-03-03 | 2023-09-06 | InterAx Biotech AG | Modulators of ackr3 and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| PE20021019A1 (es) * | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| AU2002363250A1 (en) * | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| WO2004039815A2 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases |
| WO2004064836A2 (en) | 2003-01-22 | 2004-08-05 | Pharmacia & Upjohn Company Llc | Treatment of diseases with alpha-7 nach receptor full agonists |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| JP2006525355A (ja) * | 2003-05-01 | 2006-11-09 | アボット・ラボラトリーズ | ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド |
| EP1638944A1 (en) * | 2003-06-12 | 2006-03-29 | Eli Lilly And Company | Tachykinin receptor antagonists |
| US20110060017A1 (en) | 2008-03-11 | 2011-03-10 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| US20100179186A1 (en) | 2008-10-10 | 2010-07-15 | University Of Kentucky Research Foundation | USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS |
| WO2012177263A1 (en) | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
-
2011
- 2011-06-24 WO PCT/US2011/041866 patent/WO2012177263A1/en not_active Ceased
-
2012
- 2012-06-22 BR BR112013033306A patent/BR112013033306A2/pt not_active IP Right Cessation
- 2012-06-22 JP JP2014517231A patent/JP6087911B2/ja active Active
- 2012-06-22 CN CN201280035785.5A patent/CN103717069B/zh active Active
- 2012-06-22 ES ES12802484.1T patent/ES2627338T3/es active Active
- 2012-06-22 RU RU2014102191A patent/RU2610094C2/ru not_active IP Right Cessation
- 2012-06-22 US US14/127,699 patent/US9108949B2/en active Active
- 2012-06-22 WO PCT/US2012/043813 patent/WO2012178057A1/en not_active Ceased
- 2012-06-22 WO PCT/US2012/043880 patent/WO2012178112A1/en not_active Ceased
- 2012-06-22 EP EP12802484.1A patent/EP2723173B1/en active Active
- 2012-06-22 US US14/128,378 patent/US9469625B2/en active Active
- 2012-06-22 MX MX2014000255A patent/MX342322B/es active IP Right Grant
- 2012-06-22 CA CA2840373A patent/CA2840373A1/en not_active Abandoned
- 2012-06-22 AU AU2012272646A patent/AU2012272646B2/en not_active Ceased
- 2012-06-22 KR KR1020147000636A patent/KR20140036305A/ko not_active Withdrawn
- 2012-06-22 CA CA2840047A patent/CA2840047A1/en not_active Abandoned
- 2012-06-22 AU AU2012272680A patent/AU2012272680A1/en not_active Abandoned
-
2013
- 2013-12-19 IL IL230036A patent/IL230036A/en active IP Right Grant
-
2015
- 2015-06-17 US US14/742,570 patent/US9452160B2/en active Active
-
2016
- 2016-01-11 US US14/993,048 patent/US9708294B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014000255A (es) | 2014-08-21 |
| EP2723173A4 (en) | 2015-02-18 |
| KR20140036305A (ko) | 2014-03-25 |
| WO2012178057A1 (en) | 2012-12-27 |
| JP2014517078A (ja) | 2014-07-17 |
| CN103717069A (zh) | 2014-04-09 |
| US9108949B2 (en) | 2015-08-18 |
| WO2012177263A1 (en) | 2012-12-27 |
| ES2627338T3 (es) | 2017-07-27 |
| AU2012272680A1 (en) | 2014-02-20 |
| CA2840373A1 (en) | 2012-12-27 |
| US20140205595A1 (en) | 2014-07-24 |
| EP2723173A1 (en) | 2014-04-30 |
| US20160008343A1 (en) | 2016-01-14 |
| JP6087911B2 (ja) | 2017-03-01 |
| US9452160B2 (en) | 2016-09-27 |
| CA2840047A1 (en) | 2012-12-27 |
| US9708294B2 (en) | 2017-07-18 |
| US20140205596A1 (en) | 2014-07-24 |
| BR112013033306A2 (pt) | 2016-08-16 |
| IL230036A (en) | 2016-10-31 |
| US20160237061A1 (en) | 2016-08-18 |
| AU2012272646A1 (en) | 2014-02-20 |
| US9469625B2 (en) | 2016-10-18 |
| CN103717069B (zh) | 2018-06-05 |
| RU2610094C2 (ru) | 2017-02-07 |
| RU2014102191A (ru) | 2015-07-27 |
| AU2012272646B2 (en) | 2016-09-08 |
| WO2012178112A1 (en) | 2012-12-27 |
| EP2723173B1 (en) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500960A1 (en) | Processes for preparing isoquinolinones and solid forms of isoquinolinones | |
| PH12018502500A1 (en) | Methods and compositions for determining resistance to androgen receptor therapy | |
| MX342322B (es) | Compuestos organicos. | |
| WO2013056148A3 (en) | Scd1 antagonists for treating cancer | |
| GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
| EA201391332A1 (ru) | Лиганды опиоидных рецепторов и способы их применения и получения | |
| MX2015005831A (es) | Antagonistas de il-6 y usos de los mismos. | |
| MX339899B (es) | Compuestos de triazolopiridina como inhibidores de pim cinasa. | |
| IN2014KN02906A (https=) | ||
| MX2015002873A (es) | Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
| NZ758528A (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12013502201A1 (en) | Anti-b7-h3 antibody | |
| JO3092B1 (ar) | مركب لتحفيز مسيطر عليه للمبيض | |
| MX360774B (es) | Antagonistas de progesterona. | |
| MX352881B (es) | Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2. | |
| EA201391114A1 (ru) | Способы использования alk-ингибиторов | |
| MX2014006514A (es) | Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4). | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| EA201491013A1 (ru) | Пиразиновые ингибиторы киназы | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| TW201613884A (en) | Selective NR2B antagonists | |
| MX2014009750A (es) | Composiciones antifungicas para el tratamiento de piel y uñas. | |
| MX356412B (es) | Anticuerpos anti-kdr y metodos de uso. | |
| MX360001B (es) | Compuestos de acrilamida como ligandos receptores de histamina h3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |